Linea will migrate to the RISC-V architecture
Foresight News reports that the Ethereum L2 project Linea announced on Twitter that its cryptography researcher Alexandre Belling revealed at Ethproofs that Linea will transition to the RISC-V architecture. The main reason is that every Ethereum hard fork requires a complete rewrite of the constraint module, causing the team to focus on managing complexity long-term rather than advancing cutting-edge performance. RISC-V offers only 32 registers and approximately 40 instructions. For proof systems, the narrower tracking range allows for real-time construction, and provers can immediately start processing proof segments. In addition, RISC-V provides a more concise execution trace and Type-1 compatibility, while retaining zkC (constraint native language), Vortex and Arcane (proof/aggregation stack), as well as formal verification.
Linea stated that this move is highly aligned with the RISC-V roadmap being promoted by the Ethereum Foundation, and more technical details will be announced in the coming weeks.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
